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Increasing evidence suggests a role for endothelial cell (EC) dysfunction in pathogenesis
of cerebral small vessel disease. Commonly used medications including certain
antihypertensives and statins have EC-stabilizing effects. We used individual patient data
from completed acute stroke trials to assess whether prior exposure to EC-stabilizing
medications was associated with lacunar stroke, using lacunar stroke as a clinical proxy
for cerebral small vessel disease. Across 12,002 patients with relevant data, 2,855 (24%)
had a lacunar stroke presentation. Univariable analyses suggested potential confounding
from vascular diseases treated with EC-stabilizing medications. Initial multivariable
logistic regression gave conflicting results when describing the independent association
of exposure to EC-stabilizing medication and lacunar stroke in the complete population
(O.R. 0.87, 95% C.I.: 0.77– 0.98) and limited to those taking any antihypertensive (O.R.
1.51, 95%C.I.: 1.21–1.88). Re-running the analyses including statins in the EC-stabilizing
category suggested a beneficial effect of EC-stabilizing medication exposure on lacunar
stroke incidence (O.R. 0.83, 95% C.I.: 0.73–0.93). These results align with recent
pre-clinical data and would support interventional trials of EC-stabilizing medication
for preventing cerebral small vessel disease. Our results also suggest that analyses
of EC-stabilizing interventions need to adjust for potential endothelial effects of other
co-prescribed medication.
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INTRODUCTION
Cerebrovascular small vessel disease (SVD) is common, increases with age (1) and accounts
for almost half of all dementias (2), one fifth of all strokes (3), especially lacunar strokes, and
more than four fifths of all intracerebral hemorrhages (4). Neuropathological features of SVD
include progressive changes in the perforating arterioles, capillaries, and venules, eventually
causing cerebral white and deep gray matter damage (5, 6), and accompanied by characteristic
neuroradiological changes on brain imaging (7, 8).
Recently, mechanistic links have been shown between dysfunction of endothelial cells (EC)
in cerebral small blood vessels and white matter damage in a rat model of SVD and also in
human SVD tissue (9). EC dysfunction is defined as a state where there is less available NO, more
Becker et al. Endothelium Stabilizers and Lacunar Stroke
proliferation, reduced tight junctions between cells and increased
production of HSP90a (10). SVD patients have elevated plasma
levels of biomarkers of EC dysfunction, such as ICAM-1 (11)
and a reduced vasodilatory response to vasoactive challenges
(12). The pathological changes of EC dysfunction and white
matter damage in a rat model of SVD were reversed by use of
drugs known to stabilize endothelial function, by increasing nitric
oxide production (9). EC-stabilizing drugs included perindopril
(an Angiotensin Converting Enzyme Inhibitor) and simvastatin
(a HMG Co-A reductase inhibitor), both are drugs that are in
common use in clinical practice.
One question raised by this work is whether SVD is also
reversible in humans, and clinical trials are in progress which
may help answer this (LACI-1 (13, 14) and LACI-2) (Clinical
trials: ISRCTN12580546, ISRCTN14911850). These trials have
chosen drugs reversing endothelial dysfunction, due to the
hypothesis that SVD is not primarily caused by hypertension
(15) or atheroma (16). Classes of drugs with potential endothelial
benefit have been used to reduce cardiovascular risk for many
years, and so this provides an opportunity to examine clinical
data as a first step to answering this question. Trials of
antihypertensives in reducing SVD-related strokes have shown
conflicting results, with some showing a benefit and others not
[reviewed in (17)]. This may be in part as the hypothesis tested
was whether lowering blood pressure (using any medication)
reduces incidence of lacunar stroke. Within the antihypertensive
rubric are various drug classes with differing modes of action
and not all will have endothelial effects. An alternative question
is whether medications that stabilize endothelial cells or reverse
their dysfunction regardless of their effect on hypertension
are effective in reducing SVD. In support of this, trials using
angiotensin converting enzyme inhibitors (18) or statins (19)
(both EC-stabilizing) have shown reduction in the progression
of neuroimaging features of SVD. The overall contribution of
classical vascular risk factors to SVD burden is modest and we
feel that there is a need for research looking at novel risk factors
(20) and that recognizes the interaction of vascular disease with
other processes (21).
We utilized existing stroke trial data to test our hypothesis
that use of medications with EC-stabilizing function is associated
with reduced SVD. As SVD is often clinically covert, we have
used the more clinically obvious manifestation of cerebral SVD
of lacunar stroke. We firstly compared incidence of lacunar
stroke between patients exposed to antihypertensives with and
without EC-stabilizing properties. We then assessed association
of lacunar stroke with exposure to statins, which also are known
to stabilize EC function without altering blood pressure.
MATERIALS AND METHODS
We created a case-control experiment with two groups: patients
takingmedications associated with EC-stabilizing effects (defined
using various criteria as described below) and those not taking
these drugs. We analyzed the association of prior exposure of
EC-stabilizing drugs using clinical lacunar strokes as a proxy for
SVD. Using lacunar stroke events as a proxy for SVD is attractive
as it can be determined from stroke records in retrospect,
with typical clinical features of pure motor hemiparesis, pure
sensory syndrome, sensorimotor stroke, ataxic hemiparesis, or
dysarthria-clumsy hand.
Dataset
We used the Virtual International Stroke Trials Archive (VISTA)
as our data source. VISTA is a not-for-profit organization that
archives anonymized, patient level data from completed stroke
trials (22). We extracted individual patient data from the VISTA
resource that allowed characterization of stroke type, pre-stroke
medication history, cardiovascular risk factors, age, sex, and
mortality. The data were taken from completed acute stroke trials
and so all included patient data were from patients with a stroke
event. The use of fully anonymized data from VISTA for novel
research purposes has Institutional ethical approval (University
of Glasgow, MVLS ethics). These data were all from studies
within this involving human participants that were in accordance
with the ethical standards of the institutional and national
research committee and with the 1964 Helsinki declaration and
its later amendments, including informed consent.
Exposure
The first exposure of interest was antihypertensive therapy prior
to stroke. We defined drugs that stabilize EC function as those
known to increase the production of nitric oxide (NO) by
finding any peer-reviewed publication with evidence of this by
examination of the literature (Supplementary Table 1). Drugs
were defined separately, rather than in their groups, as for
example, some betablockers are known to be EC-stabilizing and
others are not. Each of the approximately 168,000 medications
contained in our VISTA file was classified, by evidence in the
literature, into:
1) Antihypertensive medications that stabilize ECs
2) Antihypertensive medications that do not stabilize ECs
3) Mixed preparations (drug combinations with stabilizing and
non-stabilizing effects)
4) Non-antihypertensive medications without EC-stabilizing
effects
Group 1 and 3 medications were grouped together as EC-
stabilizing. Where a patient was taking more than one
antihypertensive drug, if any belonged to the EC-stabilizing
group, then the patient was classified into the EC-stabilizing
antihypertensive exposed group. Patients taking these agents for
reasons other than hypertension, such as migraine, arrhythmia,
or benign prostate hyperplasia were included as we were
interested in endothelial effect rather than blood pressure effect
per se. Only oral agents were considered. As a secondary analysis,
we included statins as medications that stabilize EC function,
though without anti-hypertensive properties. Exposure to any
statin was classified as EC-stabilizing. The dose and duration of
these medications for each patient was not available. Thus, any
exposure was included.
A list of the statins, antihypertensive drugs and their
categorization is provided in Supplementary Tables 1, 2.
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Outcome
The outcome of interest was lacunar stroke, the most
recognizable clinical manifestation of SVD and used here
as a proxy for SVD. We used a multimodal approach to classify
patients as having lacunar or non-lacunar stroke. We used the
Oxfordshire Clinical Stroke Project classification (OSCP) (23)
to categorize stroke type retrospectively and in particular to
identify lacunar strokes (LACS). Where the OCSP classification
was absent, we used the National Institute of Health Stroke Scale
(NIHSS) to exclude patients on the basis of cortical impairments
that were not compatible with a lacunar stroke presentation.
We ensured that the final selection of patients all had a clinical
presentation in keeping with a recognized lacunar stroke
syndrome: pure motor, pure sensory, or pure sensory-motor
(Figure 1). Radiological data were not used.
Analyses
In our initial analyses, we classified EC-stabilizing medication
exposure based on antihypertensive medication only. Our
analyses were based on a protocol that was reviewed and
approved by the VISTA steering committee. We made the a-
priori decision to use multivariable logistic regression for our
primary analyses as we felt that this approach made the fewest
assumptions and allowed greatest use of the available data. We
performed initial univariable proportional (chi square) analyses
to describe associations between exposure to EC-stabilizing
medication and lacunar stroke. We then used multivariable
models to correct for potential clinical and demographic
confounders, specifically focusing on those conditions associated
with prescription of a particular antihypertensive. Co-variables of
interest were: age; sex; history of hypertension; atrial fibrillation;
myocardial infarction; diabetes mellitus; and previous stroke.
Choice of variable for inclusion in the multivariable model
was based on biological plausibility and previous research on
small vessel disease. As per best practice in these analyses,
the choice for inclusion was not based solely on univariate
associations. However, there were no data available for how well
co-morbid conditions were controlled. We employed backwards
logistic regression against an outcome of lacunar stroke and
presented the resulting data as odds ratios (O.R.) and associated
95% confidence intervals (C.I.). As a further adjustment for
the potential indication bias of antihypertensive medication, we
re-ran the univariable and multivariable analyses limiting the
included population to those taking antihypertensivemedication.
We repeated the multivariable analyses to study the effect
of statin exposure. Firstly, we added statin exposure into
the multivariable model. We then re-ran the multivariable
analysis, creating a new exposed population that included both
patients taking EC-stabilizing antihypertensives and statins.
Finally, we performed post-hoc exploratory analyses to study
differences in 90 day mortality between exposed and non-
exposed groups, where the exposed group was firstly those
taking EC-stabilizing antihypertensives and then those taking
EC-stabilizing antihypertensives and/or statins. For these binary
regression models, we calculated that we needed at least 90
outcomes (lacunar stroke) for a model that contained all nine
variables of interest and thus we were confident that our sample
had adequate power for primary and all subgroup analyses. All
analyses were performed using SPSS (Version 1.0.0.7, IBM).
RESULTS
Our dataset included 12,002 patients taking 168,000 medications.
Of these patients, we defined 2,855 (24%) as having lacunar
strokes. Of these patients, 2,276 had NIHSS data suitable
for analysis for the subtype of lacunar stroke with 1,020
sensorimotor, two pure sensory, 735 pure motor, 205 ataxic
hemiparesis, one dysarthria-clumsy hand, and 313 other. The
small number of pure sensory strokes likely relates to RCT
inclusion criteria, where a minimum level of NIHSS would
be needed to be eligible for inclusion. However, we did not
subdivide the lacunar strokes types in further analysis. Of the
total included patients, 8,025 patients had been exposed to
antihypertensive medications (6,671 to antihypertensives that
stabilize EC function and 1,354 as exposed to antihypertensives
that do not stabilize EC function) and 3,978 were not taking any
antihypertensive medication (Figure 1A). Of the 9,147 patients
with non-lacunar strokes, there was information for stroke
subtype for 9,089 patients, and 8,652 patients had an ischaemic
stroke and 437 a haemorrhagic stroke.
First, we asked whether, in the entire dataset, there was
a difference in the proportion of lacunar strokes between
patients taking EC-stabilizing antihypertensivemedications prior
to stroke and those who are not. On unadjusted testing including
all patients, there was a lower proportion of lacunar stroke
in those exposed to EC-stabilizing antihypertensive medication
(Table 1). This was in spite of the higher incidence of diabetes
mellitus, atrial fibrillation, previous stroke and hypertension in
the patients taking EC-stabilizing antihypertensives. However,
when we confined the analysis to the population treated with
any antihypertensive medications, there were more lacunar
strokes found in patients taking EC-stabilizing antihypertensives
(Supplementary Table 3). Again, this treatment group was more
likely to have been diagnosed as having hypertension and
diabetes mellitus.
Due to the possible confounding of vascular conditions
that may be treated with EC stabilizing medication, we used
multivariable logistic regression to determine whether exposure
to EC stabilizing antihypertensives was independently associated
with lacunar strokes in both the entire dataset and in the group
taking any antihypertensive medication as before. Comparing
those on an EC-stabilizing antihypertensive with the rest of the
dataset, the O.R. of having a lacunar stroke was significantly
less if the patient was taking an EC-stabilizing antihypertensive
(O.R. 0.87, 95% C.I.: 0.77–0.98; Table 2). When repeating the
analysis confined to only those patients taking antihypertensive
medications the O.R. of having a lacunar stroke was significantly
greater if the patient was taking an EC-stabilizing anti-
hypertensive (O.R. 1.51, 95% C.I.: 1.21–1.88; Table 3).
To assess these seemingly inconsistent results, we considered
the possibility that statins, which have EC-stabilizing properties
but no antihypertensive effect, may be a confounding factor. In
our dataset, a total 3,092 patients were taking statins (Figure 1B).
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FIGURE 1 | (A) Flowchart of strategy for identifying patients with lacunar stroke and their numbers on anti-hypertensives that are endothelial cell-stabilizing or not.
(B) Flowchart of strategy for identifying patients with lacunar stroke and their numbers on endothelial cell-stabilizing medications including statins.
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TABLE 1 | Univariable analysis comparing all patients exposed or not to
endothelial cell-stabilizing antihypertensive medication.
Exposed to
EC-stabilizing
anti-HT drug N = 6,671
Not-exposed to
EC-stabilizing anti-HT
drug N = 5,331
P
Female 3,024 2,314 0.03
Hypertension history 4,840 2,342 <0.0001
Diabetes Mellitus 1,456 796 <0.0001
Myocardial Infarct 833 584 0.23
Atrial fibrillation 1,649 981 <0.0001
Previous stroke 1,400 1,413 <0.0001
Lacunar stroke 1,515 (23%) 1,340 (25%) 0.002
Non-lacunar stroke 5,156 (77%) 3,991 (75%)
EC, Endothelial cell; HT, hypertensive.
The final cell reports significance testing for comparative analysis comparing
proportion of lacunar stroke in those exposed and non-exposed to EC stabilizing
antihypertensive medication.
TABLE 2 | Multivariable model (logistic regression) describing odds ratios of
lacunar stroke including all patients.
Odds ratio (95% CI) P
Increasing age (+1 year) 0.98 (0.98–0.98) <0.0001
Male 1.07 (0.96–1.20) 0.25
Hypertension history 1.03 (0.90–1.18) 0.63
Diabetes Mellitus 1.05 (0.92–1.20) 0.51
Myocardial Infarct 0.81 (0.69–0.96) 0.015
Atrial fibrillation 0.48 (0.41–0.56) <0.0001
Previous stroke 1.82 (1.6–2.1) <0.0001
EC stabilizing anti-HT drug 0.87 (0.77–0.98) 0.017
EC, Endothelial cell; HT, hypertensive.
Firstly, we added statin exposure as a variable to the multivariable
model using the complete dataset. In this revised analysis,
statins were independently associated with a reduction in the
likelihood of lacunar stroke (O.R. 0.73, 95% C.I.: 0.63–0.84)
while the association between EC stabilizing antihypertensive
medication and reduction in lacunar stroke was lost (Table 4).
When we re-ran the multivariable model with a new exposure
classification that included both patients exposed to relevant
antihypertensive medication and statins, then the EC-stabilizing
medication exposed group had a significantly lower O.R. of
having a lacunar stroke (O.R. 0.83, 95% C.I.: 0.73–0.93; Table 5).
To assess whether there was also an association between
exposure to EC-stabilizing medication and clinical outcome we
performed a post-hoc exploratory analysis. For this, we used
data for 90 day mortality post stroke. There was no change
in mortality associated with taking an anti-hypertensive EC-
stabilizing medication but exposure to statins was associated with
a significant increased odds of being alive at 90 days (O.R. 1.49,
95% C.I.: 1.26–1.76). When we ran the analysis again, this time
including statin exposure in the EC stabilizing group a reduction
in 90 day mortality was seen for those taking EC stabilizing
medications (O.R. 1.15, 95% C.I.: 1.00–1.32; Table 6).
TABLE 3 | Multivariable model (logistic regression) describing odds ratios of
lacunar stroke including only patients exposed to antihypertensive medication.
Odds ratio (95% CI) P
Increasing age (+1 year) 0.97 (0.97–0.98) <0.0001
Male 1.01 (0.87–1.18) 0.86
Hypertension history 1.24 (1.02–1.5) 0.03
Diabetes mellitus 0.95 (0.8–1.13) 0.58
Myocardial Infarct 0.87 (0.7–1.08) 0.22
Atrial fibrillation 0.49 (0.4–0.59) <0.0001
Previous stroke 1.75 (1.5–2.0) <0.0001
EC stabilizing anti-HT drug 1.51 (1.21–1.88) <0.0001
EC, Endothelial cell; HT, hypertensive.
TABLE 4 | Multivariable model (logistic regression) describing odds ratios of
lacunar stroke including all patients and adding statin exposure as a variable.
Odds ratio (95% CI) P
Increasing age (+1 year) 0.98 (0.98–0.98) <0.0001
Male 1.06 (0.96–1.21) 0.0223
Hypertension history 1.03 (0.90–1.17) 0.72
Diabetes Mellitus 1.04 (0.91–1.19) 0.53
Myocardial Infarction 0.83 (0.70–0.98) 0.027
Atrial fibrillation 0.47 (0.40–0.55) <0.0001
Previous stroke 1.79 (1.58–2.02) <0.0001
Statin 0.73 (0.63–0.84) <0.0001
Antihypertensive EC-stabilizer 0.93 (0.83–1.06) 0.27
EC, Endothelial cell; HT, hypertensive.
TABLE 5 | Multivariable model (logistic regression) comparing all patients
describing odds ratio of lacunar stroke where endothelial cell stabilizers include
both antihypertensive and statin medications.
Odds ratio (95% CI) P
Increasing age (+1 year) 0.98 (0.97–0.98) <0.0001
Male 1.07 (0.96–1.20) 023
Hypertension history 1.04 (0.91–1.19) 0.55
Diabetes Mellitus 1.05 (0.91–1.20) 0.52
Myocardial Infarct 0.81 (0.69–0.96) 0.014
Atrial fibrillation 0.48 (0.41–0.56) <0.0001
Previous stroke 1.80 (1.59–2.03) <0.0001
EC stabilizer—both statin and anti-HT combined 0.83 (0.73–0.93) 0.001
EC, Endothelial cell; HT, hypertensive.
DISCUSSION
Due to our previous findings of EC-stabilizing medication
reversing SVD pathology in a rat model (9), we took a novel
approach of using pre-existing stroke trial data to test for an
association between exposure to EC-stabilizing drugs and lacunar
stroke in humans, allowing us to search a large amount of data.
We demonstrated an association between use of these drugs
and reduction in lacunar stroke and therefore by extrapolation
a potential protective effect of these medications on SVD. This
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TABLE 6 | Multivariable model (logistic regression) describing 90 day post-stroke
mortality.
Odds ratio (95% CI) P
Increasing age (+1 year) 1.05 (1.04–1.05) <0.0001
Female 0.87 (0.77–0.98) <0.0001
Hypertension history 0.91 (0.78–1.05) 0.19
Diabetes mellitus 0.82 (0.71–0.94) 0.006
Myocardial Infarct 0.68 (0.58–0.81) <0.0001
Atrial fibrillation 0.69 (0.61–0.79) <0.0001
Previous stroke 0.86 (0.76–0.99) 0.029
EC anti–HT stabilizer 1.15 (1.00–1.32) 0.047
Lacunar stroke 4.10 (3.28–5.21) <0.0001
Data presented are odds of being alive at 90 days follow-up.
EC anti-HT stabilizer - endothelial cell-stabilizing antihypertensive medication and/or
statin medication.
effect appears to be independent of reducing hypertension and
lends further support to a role for EC dysfunction in the
pathogenesis of SVD.
When designing the study, we recognized that a retrospective
secondary analysis of clinical trial datasets had potential for
bias and confounding. In particular, medications with EC-
stabilizing effects are commonly prescribed in large vessel
and cardiac disease. Our initial unadjusted analysis confirmed
that cardiovascular risk factors were associated with lacunar
stroke and had to be included in any model exploring the
relationship between EC-stabilization and SVD. As SVD is
associated with hypertension and as antihypertensives were our
primary medication exposure of interest, we accounted for
antihypertensive confounding using two methods; we included
history of hypertension in our models and also restricted analyses
to a subgroup of the population, removing those who had no
exposure to any antihypertensive.
These initial analyses, considering EC-stabilizing medication
exposure based on antihypertensive medication history only,
gave unexpected and seemingly conflicting results. We had pre-
specified statin use as a secondary analysis of interest, but the
high proportion of patients in the dataset taking statins suggested
that statins had to be accounted for in all our analyses. The
potential beneficial effect of statins was confirmed in our revised
analyses. The analyses including those taking any EC-stabilizing
medication (statin and/or antihypertensive) is arguably the most
robust and in this model EC-stabilizing exposure was associated
with less lacunar strokes. This appeared independent of a
reduction in blood pressure as there was a stronger reduction
in the odds of a SVD-type stroke than in the group taking
EC-stabilizing antihypertensives alone. The post-hoc analyses
describing outcomes following stroke are aligned with our other
findings and further support that statins have important effects
and should be included in any study looking to describe EC-
stabilizing medications. However, as a note of caution, we do not
have data on cause of death as an outcome and so were unable to
separate neurological from non-neurological mortality.
Our analyses demonstrate that large trial resources can be
used for hypothesis testing and development and may be a
potential platform for selecting agents that could be repurposed
for SVD indications specifically. Our analyses also highlight
important methodological considerations for future studies of
EC-stabilizing medications, most notably the need to adjust
analyses for other vascular risk factors and the limitations of
considering a single drug group in isolation. Polypharmacy was
the norm in this dataset, a feature also seen in real world clinical
practice. While we strived for scientific purity in our initial
analyses restricted to antihypertensives only, it was only when we
also included statins that the results became consistent.
Secondary analysis of existing data is an approach with many
caveats to its interpretation. However, using data in this way
offers cost and time efficiency, allowing hypothesis exploration
in a large cohort of well-phenotyped patients. Many of our
results are in keeping with our current understanding of stroke
epidemiology and suggest face validity of our analyses, for
example the consistent strong negative association of atrial
fibrillation and lacunar stroke.
We recognize the limitations of such analyses. Our VISTA
data (22) contained information only on patients in stroke
trials, therefore we could only assess one stroke type against
another. The ideal would be a primary intervention study using
prospective follow-up of a healthy cohort treated or untreated
with EC-stabilizing medications with incidence of SVD as an
outcome. Such primary outcome data may be obtainable in
time from the UK Biobank (http://www.ukbiobank.ac.uk/) or
other large prospective population studies when numbers allow.
Furthermore, we recognize that there are many approaches to
assessing for associations in observational data. Other approaches
would include matching or more sophisticated propensity
scoring, but ultimately there is no perfect analysis and residual
bias is always a possibility when assessing observational data
to make causal inferences. We also accept that we may be
underestimating the incidence of SVD by using clinical lacunar
stroke as a proxy, however, it is at least a robust outcomemeasure.
SVD also causes the symptoms of cognitive decline and dementia
(24), which we were unable to identify in this dataset, but which
would be interesting to include in a prospective dataset. We
did not have available dose or exposure duration data for these
medications, but had to pragmatically assign exposure as “yes”
or “no”: a dose response would increase our confidence in this
association. Association is not synonymous with causation but
our results align with evidence from animal studies in models of
SVD and from human post mortem brain.
Small vessel disease (SVD) and associated lacunar strokes have
been under-studied and yet the suggestion that this mechanism
of disease is reversible in rat models (9) and in humans (25)
could have major socio-economic impact. If the results of our
analyses are proven to be true then there is the potential that
standard, safe, and cheap medications may be used to reduce
the physical and cognitive disability of progressive cerebral SVD.
This is particularly important as to date we have no proven
therapies for SVD, and only limited neuroradiological proof in
humans that this may be reversible (25). Based on our data and
other emerging preclinical and neuroimaging studies, we now at
least have logic in moving to prospective interventional studies
and this should be the next step for this common disease.
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